Gilead Sciences Inc (GILD)
Gilead - Gilead’s Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)
Gilead - Gilead’s Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)
📊 **NEUTRAL** • Medium confidence analysis (70%) • Weak signals • Minimal impact expected **Sentiment:** Neutral (50%) **Content type:** General